Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 22

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 22
---

or unauthorized use, we may be required to file claims, and any related litigation and/or prosecution of such claims can be expensive
and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging
that we infringe their intellectual property. In addition, in a patent infringement proceeding, a court may decide that a patent of ours
is invalid in whole or in part, unenforceable, or construe the patent’s claims narrowly allowing the other party to commercialize
competing products on the grounds that our patents do not cover such products.

Even if resolved in our favor,
litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract
our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase
our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources
to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings
more effectively than we can because of their substantially greater financial resources. The effects of patent litigation or other proceedings
could therefore have a material adverse effect on our ability to compete in the marketplace.

Confidentiality and invention assignment
agreements with our employees, advisors and consultants may not adequately prevent disclosure of trade secrets and protect other proprietary
information.

We consider proprietary trade
secrets and/or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets and/or confidential
know-how to protect our technology, especially where patent protection is believed by us to be of limited value. However, trade secrets
and/or confidential know-how can be difficult to maintain as confidential.

To protect this type of information
against disclosure or appropriation by competitors, our policy is to require our employees, advisors and consultants to enter into confidentiality
and invention assignment agreements with us. However, current or former employees, advisors and consultants may unintentionally or willfully
disclose our confidential information to competitors, and confidentiality and invention assignment agreements may not provide an adequate
remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and
is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality
and invention assignment agreements may vary from jurisdiction to jurisdiction.

Failure to obtain or maintain
trade secrets and/or confidential know-how trade protection could adversely affect our competitive position